Royalty Pharma (RPRX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $59.62, +1.07% vs the prior close of $58.99.
- Volume 3.41M shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RPRX rises 1.1% to $59.62, a 1-month high. Closed at $59.62, +1.07% vs the prior close of $58.99. Day range $59.50–$60.41, opened at $59.75.
RPRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — RPRX rises 1.1% to $59.62, a 1-month high
- Closed at $59.62, +1.07% vs the prior close of $58.99. Day range $59.50–$60.41, opened at $59.75.
- Volume was 3.41M shares, 1.1x its 50-day average of 3.01M.
- Price is +0.7% vs its 50-day average ($59.21) and +14.8% vs its 200-day average ($51.91).
- 52-week range $35.79–$64.38; today's close sits at 83% of that range, 7.4% below the 52-week high.
Oct 14, 2026 — RPRX jumps 4.3% to $58.99, a 1-month high
- Closed at $58.99, +4.28% vs the prior close of $56.57. Day range $56.78–$59.08, opened at $56.93.
- Volume was 2.83M shares, 0.9x its 50-day average of 3.02M.
- Price is -0.3% vs its 50-day average ($59.17) and +13.9% vs its 200-day average ($51.81).
- 52-week range $35.50–$64.38; today's close sits at 81% of that range, 8.4% below the 52-week high.
Oct 13, 2026 — RPRX dips 2.1% to $56.57
- Closed at $56.57, -2.09% vs the prior close of $57.78. Day range $56.42–$57.97, opened at $57.70.
- Volume was 3.58M shares, 1.2x its 50-day average of 3.01M.
- Price is -4.3% vs its 50-day average ($59.14) and +9.4% vs its 200-day average ($51.71).
- 52-week range $35.23–$64.38; today's close sits at 73% of that range, 12.1% below the 52-week high.
Oct 12, 2026 — RPRX rises 1.5% to $57.78
- Closed at $57.78, +1.49% vs the prior close of $56.93. Day range $56.85–$57.92, opened at $57.04.
- Volume was 2.47M shares, 0.8x its 50-day average of 3.00M.
- Price is -2.3% vs its 50-day average ($59.15) and +11.9% vs its 200-day average ($51.63).
- 52-week range $35.23–$64.38; today's close sits at 77% of that range, 10.3% below the 52-week high.
Oct 9, 2026 — RPRX rises 1.3% to $56.93
- Closed at $56.93, +1.28% vs the prior close of $56.21. Day range $55.72–$57.08, opened at $56.03.
- Volume was 2.88M shares, 1.0x its 50-day average of 3.00M.
- Price is -3.8% vs its 50-day average ($59.16) and +10.5% vs its 200-day average ($51.53).
- 52-week range $35.23–$64.38; today's close sits at 74% of that range, 11.6% below the 52-week high.
Oct 8, 2026 — RPRX dips 1.0% to $56.21, a 1-month low
- Closed at $56.21, -0.97% vs the prior close of $56.76. Day range $55.13–$56.71, opened at $56.57.
- Volume was 2.85M shares, 1.0x its 50-day average of 2.99M.
- Price is -5.1% vs its 50-day average ($59.20) and +9.3% vs its 200-day average ($51.44).
- 52-week range $35.23–$64.38; today's close sits at 72% of that range, 12.7% below the 52-week high.
Oct 7, 2026 — RPRX rises 0.6% to $56.76
- Closed at $56.76, +0.57% vs the prior close of $56.44. Day range $56.40–$57.15, opened at $56.60.
- Volume was 3.67M shares, 1.2x its 50-day average of 2.98M.
- Price is -4.2% vs its 50-day average ($59.26) and +10.5% vs its 200-day average ($51.36).
- 52-week range $35.23–$64.38; today's close sits at 74% of that range, 11.8% below the 52-week high.
Oct 6, 2026 — RPRX dips 0.4% to $56.44, a 1-month low, 4 down days in a row
- Closed at $56.44, -0.39% vs the prior close of $56.66. Day range $56.04–$57.13, opened at $56.66.
- Volume was 2.43M shares, 0.8x its 50-day average of 2.96M.
- Price is -4.9% vs its 50-day average ($59.33) and +10.1% vs its 200-day average ($51.26).
- 52-week range $35.23–$64.38; today's close sits at 73% of that range, 12.3% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — RPRX dips 0.9% to $56.66, a 1-month low, 3 down days in a row
- Closed at $56.66, -0.87% vs the prior close of $57.16. Day range $56.01–$57.25, opened at $57.10.
- Volume was 3.96M shares, 1.4x its 50-day average of 2.93M.
- Price is -4.6% vs its 50-day average ($59.37) and +10.7% vs its 200-day average ($51.17).
- 52-week range $35.23–$64.38; today's close sits at 74% of that range, 12.0% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — RPRX dips 0.8% to $57.16, a 1-month low
- Closed at $57.16, -0.82% vs the prior close of $57.63. Day range $56.96–$57.91, opened at $57.63.
- Volume was 2.23M shares, 0.8x its 50-day average of 2.93M.
- Price is -3.8% vs its 50-day average ($59.42) and +11.9% vs its 200-day average ($51.08).
- 52-week range $35.23–$64.38; today's close sits at 75% of that range, 11.2% below the 52-week high.
RPRX latest news & SEC filings
Every SEC filing by or about RPRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Urist Marshall sold 4,126 shares at $57.10 (≈$235.59K) on Oct 5, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 30, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bassler Bonnie L received an award of 642 shares at $58.41 (≈$37.50K) on Sep 30, 2026; now holds 79,823
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Urist Marshall sold 4,126 shares at $57.88 (≈$238.81K) on Sep 28, 2026; now holds 4,126
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 28, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 24, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hite Christopher sold 96,073 shares at $58.51 (≈$5.62M) on Sep 22, 2026; now holds 274,328
- Hite Christopher sold 3,927 shares at $58.93 (≈$231.40K) on Sep 22, 2026; now holds 270,401
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 17, 2026 · SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $674.14M (prior year $578.66M) (+16.5% vs Jun 30, 2025)
- Net income: $17.88M (prior year $32.18M) (-44.4% vs Jun 30, 2025)
- Diluted EPS: $0.04 (prior year $0.07) (-42.9% vs Jun 30, 2025)
Aug 5, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade RPRX
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 11, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 0.98% (largest 4.3%). That is a relatively calm stock.
- Liquidity: about 3.08M shares (≈$183.84M) trade per day on average.
- 52-week position: $59.62 vs a range of $35.79–$64.38 (83% of the range).
- Dividends: last ex-dividend date Aug 14, 2026 ($0.235/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Marshall Urist sold 4,126 shares on Sep 28, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 4, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RPRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 59.75 | 60.41 | 59.50 | 59.62 | 3.41M |
| Oct 14, 2026 | 56.93 | 59.08 | 56.78 | 58.99 | 2.83M |
| Oct 13, 2026 | 57.70 | 57.97 | 56.42 | 56.57 | 3.58M |
| Oct 12, 2026 | 57.04 | 57.92 | 56.85 | 57.78 | 2.47M |
| Oct 9, 2026 | 56.03 | 57.08 | 55.72 | 56.93 | 2.88M |
| Oct 8, 2026 | 56.57 | 56.71 | 55.13 | 56.21 | 2.85M |
| Oct 7, 2026 | 56.60 | 57.15 | 56.40 | 56.76 | 3.67M |
| Oct 6, 2026 | 56.66 | 57.13 | 56.04 | 56.44 | 2.43M |
| Oct 5, 2026 | 57.10 | 57.25 | 56.01 | 56.66 | 3.96M |
| Oct 2, 2026 | 57.63 | 57.91 | 56.96 | 57.16 | 2.23M |
| Oct 1, 2026 | 58.36 | 58.40 | 57.22 | 57.63 | 3.25M |
| Sep 30, 2026 | 58.07 | 58.64 | 57.70 | 58.36 | 3.65M |
| Sep 29, 2026 | 58.19 | 58.47 | 57.51 | 58.22 | 2.89M |
| Sep 28, 2026 | 57.88 | 58.76 | 57.63 | 58.37 | 1.86M |
| Sep 25, 2026 | 58.50 | 58.50 | 57.68 | 58.21 | 1.87M |
| Sep 24, 2026 | 57.69 | 58.87 | 57.66 | 58.29 | 2.02M |
| Sep 23, 2026 | 58.52 | 59.02 | 57.63 | 57.65 | 2.80M |
| Sep 22, 2026 | 58.27 | 59.03 | 57.85 | 58.52 | 2.69M |
| Sep 21, 2026 | 58.56 | 59.06 | 57.82 | 58.44 | 3.23M |
| Sep 18, 2026 | 58.63 | 58.96 | 57.97 | 58.41 | 7.10M |
About Royalty Pharma
Royalty Pharma (RPRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: United Kingdom. Fiscal year ends December 31. SEC CIK 1802768.
RPRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Bonnie L Bassler | Director | Sep 30, 2026 |
| Vlad Coric | Director | Jun 8, 2026 |
| Catherine M. Engelbert | Director | Jun 8, 2026 |
| David C Hodgson | Director | Jun 8, 2026 |
| Carole Ho | Director | Jun 8, 2026 |
| Ted W Love | Director | Jun 8, 2026 |
| Pablo G. Legorreta | CEO, Chairman of the Board | Aug 7, 2026 |
| Gregory Norden | Director | Jun 8, 2026 |
| Elizabeth H Weatherman | Director | Jun 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Terrance P. Coyne | EVP & CFO | Aug 17, 2026 |
| Christopher Hite | EVP & Chairman, Partnering | Sep 24, 2026 |
| Pablo G. Legorreta | CEO, Chairman of the Board | Aug 7, 2026 |
| George W. Lloyd | EVP, Investments & CLO | Dec 19, 2025 |
| Arthur Richard Mcgivern | EVP, Investments & GC | Jan 6, 2026 |
| Marshall Urist | EVP, Research & Investments | Sep 30, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 28, 2026 | Marshall Urist | Sale | 4,126 | $57.88 |
| Sep 22, 2026 | Christopher Hite | Sale | 96,073 | $58.51 |
| Sep 22, 2026 | Christopher Hite | Sale | 3,927 | $58.93 |
| Aug 18, 2026 | Christopher Hite | Sale | 100,000 | $59.97 |
| Aug 13, 2026 | Terrance P. Coyne | Sale | 9,230 | $58.59 |
| Aug 13, 2026 | Terrance P. Coyne | Sale | 1,772 | $59.14 |
| Jul 1, 2026 | Marshall Urist | Sale | 9,099 | $55.88 |
| Jun 30, 2026 | Christopher Hite | Sale | 2,554 | $57.10 |
| Jun 30, 2026 | Christopher Hite | Sale | 97,446 | $56.50 |
| Jun 30, 2026 | Christopher Hite | Sale | 600 | $57.09 |
| Jun 30, 2026 | Christopher Hite | Sale | 29,400 | $56.44 |
| Jun 24, 2026 | Marshall Urist | Sale | 9,098 | $55.18 |
| Jun 23, 2026 | Christopher Hite | Sale | 117,592 | $54.47 |
| Jun 23, 2026 | Christopher Hite | Sale | 32,408 | $54.11 |
| May 26, 2026 | Terrance P. Coyne | Sale | 64,399 | $53.98 |
RPRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.38B | $770.95M | 1.78 | $2.49B |
| Dec 31, 2024 | $2.26B | $858.98M | 1.91 | $2.77B |
| Dec 31, 2023 | $2.35B | $1.13B | 2.53 | $2.99B |
| Dec 31, 2022 | $2.24B | $42.83M | 0.10 | $2.14B |
| Dec 31, 2021 | $2.29B | $619.73M | 1.49 | $2.02B |
Latest balance sheet: total assets $19.82B, total liabilities $10.03B, cash $811.99M (as of Jun 30, 2026).
RPRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $57.75 |
| May 6, 2026 | 8-K Item 2.02 (results) | $50.72 |
| Feb 11, 2026 | 8-K Item 2.02 (results) | $44.25 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $40.42 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $37.12 |
| May 8, 2025 | 8-K Item 2.02 (results) | $33.10 |
| Feb 11, 2025 | 8-K Item 2.02 (results) | $32.25 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $29.49 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $26.64 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 15, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on RPRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.